Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF2 | Q12772 | 17/20 | 0.84 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | ATM | Q13315 | 3/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282744 | 0.91 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4284306 | 0.86 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL19887431 | 0.85 | SREBF2 (0.74) | SREBF2SREBF1MAPTATML3MBTL1 | |
| Fatostatin SCHEMBL2742732 | 0.84 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| Fatostatin SCHEMBL29458338 | 0.84 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL22122181 | 0.83 | SREBF2 (0.75) | SREBF2SREBF1MAPTATML3MBTL1 | |
| Fatostatin SCHEMBL25327929 | 0.83 | MAPT (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4285116 | 0.83 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL4285022 | 0.83 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 | |
| SCHEMBL29458330 | 0.83 | SREBF2 (1.00) | SREBF2SREBF1MAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120580-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS | BAYLOR COLLEGE MEDICINE (US) | 2017-12-27 | — | — | EP | claimed |